Trial Profile
A Study to Determine the Feasibility of Treating Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Using Autologous NY-ESO-1 Specific CD8+ T Cells With Cyclophosphamide Pre-conditioning But Without the Use of IL-2
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Mipetresgene autoleucel (Primary) ; Cyclophosphamide
- Indications Liposarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Adverse reactions
- 13 Oct 2015 Based upon the results of first 12 patients, the trial is expended to include 20 additional patients in 2 cohorts, as per Adaptimmune media release.
- 05 Aug 2014 New trial record